Back

Plasma apixaban levels and thrombin generation assay in patients with atrial fibrillation with dose reduction criteria of apixaban

2 September 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Clinical decision-making about oral anticoagulant therapy in atrial fibrillation Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Muhan Yeo

Seoul National University College of Medicine, Seoul (Korea (Republic of))

8 More presentations in this session

Presentation thumbnail
Switching from warfarin to a DOAC in frail elderly asian patients with atrial fibrillation: a nationwide population-based study
Doctor Y. Go (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Drug interactions in incident NOACs users and risk of bleeding
Doctor M. Amadori (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Impact of real-world off-label dose of Apixaban on long-term clinical outcomes in patients with atrial fibrillation and chronic kidney disease
Doctor H. Shin (Busan, KR)
Abstract Slides Video
Presentation thumbnail
Resumption of anticoagulation therapy among Non-Valvular Atrial Fibrillation (NVAF) patients with prior intracranial haemorrhage
Doctor W. Sun (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Comparing the real-world and clinical trial bleeding rates associated with oral anticoagulation treatment for atrial fibrillation
Doctor Y. Gue (Liverpool, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical decision-making about oral anticoagulant therapy in atrial fibrillation

The Event

Event poster

ESC Congress 2024

2 September 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: ASPIRE (efficacy and safety of apixaban in real-world practice in Korean frail patients with AF)
thumbnail
Congress Presentation
Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources